If requires pheresis to collect blood, partial thromboplastin time (kaolin) (PTTK) < 1.5 upper limit normal
Partial thromboplastin (PT) or partial thromboplastin time (PTT) < 1.5 x institutional upper limit
Partial thromboplastin time (PTT) within 1.5x upper limit of normal;
Partial thromboplastin time =< 1.66 times upper limit of normal
Partial thromboplastin time (PTT) at enrollment per institutional range
Partial thromboplastin time (PTT) < 1.5 x upper limit of normal (ULN)
Prothrombin and partial thromboplastin times =< 1.2 x upper limit of normal (ULN) prior to biopsy
Partial thromboplastin time (PTT) =< 1.5 x ULN
Prothrombin and partial thromboplastin times =< 1.2 x normal prior to biopsy
Partial thromboplastin time (PTT) < IULN
Partial thromboplastin time (PTT) < 1.5 x upper limit of normal (ULN)
Partial thromboplastin time (PTT) < 1.5 x ULN
Partial thromboplastin time =< 1.5 x institutional ULN obtained within 14 days of first treatment
Partial thromboplastin time (PTT) =< 1.5 x upper limit of normal (ULN)
Partial thromboplastin time (PTT) =< 1.5 x institutional ULN
Partial thromboplastin time (PTT) < 1.3 x ULN
Partial thromboplastin time (PTT) =< institution's upper limit of normal, unless receiving therapeutic low molecular weight heparin
Partial thromboplastin time (PTT) < 70 seconds (sec)
Partial thromboplastin time (PTT) =< 1.2 x ULN
Partial thromboplastin time (PTT) must be =< 2 X upper normal limit of institution's normal range; subjects on anticoagulant (such as coumadin) must have a PTT =< 5 X upper normal limit of institution's normal range
Or partial thromboplastin time [PTT] > 100 sec
Partial thromboplastin time (PTT) within normal limits (+/- 15%)
Partial bladder or partial kidney removal (eg, partial cystectomy or partial nephrectomy)
Partial thromboplastin time (PTT) =< 48 seconds (1.25 x ULN)
Partial thromboplastin time (PTT) must be =< 1.5 × upper normal limit of institution's normal range
Partial thromboplastin time (PTT) =< 1.5 x ULN
Partial thromboplastin time (PTT) < 1.5 x the upper limit of institution’s normal range
Partial thromboplastin time (PTT) =< 1.2 x IULN (if not receiving anticoagulation therapy)
Partial Thromboplastin Time (PTT) ?1.5x upper limit of normal (ULN) unless receiving therapeutic anticoagulation.
Partial thromboplastin time (PTT) =< 1.5 times the upper limit of normal
Partial thromboplastin time > 50 seconds (secs)
Partial thromboplastin time (PTT) =< 1.2 x institutional ULN
Partial thromboplastin time =< 1.66 times upper limit of normal
Partial thromboplastin time 5 seconds above ULN.
Partial thromboplastin time (PTT) < 1.5 x ULN for institution unless patient is on planned therapy with heparin or heparin-like products obtained =< 14 days prior to registration
Partial thromboplastin time (PTT) less than or equal to 1.3 x ULN
Partial thromboplastin time (PTT) < 1.5 times upper limit of normal within 14 days before enrollment
Partial thromboplastin time (PTT) =< 1.5 times the upper limit of normal
Partial thromboplastin time (PTT) =< 60
Partial thromboplastin time (PTT) =< 1.5 X institutional upper limit of normal
Partial thromboplastin time (PTT) < 1.5 x upper limit of normal (ULN)
Partial thromboplastin time (PTT) >= 45 seconds
Partial thromboplastin time (PTT) must be =< 1.5 × upper normal limit of institution's normal range
Partial thromboplastin time (PTT) < 1.2 times institutional upper limit of normal
Prothrombin and partial thromboplastin times =< 1.2 x normal prior to biopsy
Partial thromboplastin time (PTT) =< 2 x normal outside the setting of stable chronic anticoagulation therapy
Abnormal laboratory values as defined by protocol for creatinine, creatinine clearance, aspartate transaminase (AST) or alanine transaminase (ALT), total bilirubin, international normalized ration (INR), partial thromboplastin time (PTT) or activated partial thromboplastin time (aPPT), unless these abnormalities are due to underlying lymphoma
Partial thromboplastin time (PTT) =< 1.5 X institutional ULN unless patients are on therapeutic anticoagulation with warfarin
EXPANSION COHORT ONLY: Partial thromboplastin time (PTT) =< 1.5 X institutional ULN unless patients are on therapeutic anticoagulation with warfarin
Partial thromboplastin time (PTT) =< 1.2 times the ULN unless the patient is receiving therapeutic anticoagulation
Partial thromboplastin time (PTT) =< 1.2 x upper limit of normal (ULN) unless the patient is receiving therapeutic anticoagulation
Subject has acceptable coagulation studies (obtained ? 14 days prior to starting Cycle 1 Day 1) partial thromboplastin time (PTT) < 1.2 x ULN and INR ? 1.5 x ULN.
Partial thromboplastin time (PTT) < 1.2 x institutional upper limits of normal
Partial thromboplastin time (PTT) > 80
Partial thromboplastin time ? 1.5 X upper limit
Partial thromboplastin time (PTT) or activated (a)PTT =< 1.5 x upper limit of normal (ULN) per institutional laboratory range
Partial thromboplastin time (PTT) < 1.2 times the upper limit of normal
Partial thromboplastin time (PTT) =< 1.2 X ULN
Partial thromboplastin time (PTT) within normal limits (WNL)
Partial thromboplastin time (PTT) =< 60
Partial thromboplastin time (PTT) < 1.5 times the upper limit of normal (heparin, lovenox or alternative anticoagulants are acceptable)
Partial thromboplastin time (PTT) =< 2 x upper limit of normal (ULN)
PTT (partial thromboplastin time) =< 1 x ULN
Partial thromboplastin time less than 4.0 times below or above the upper or lower limit range
Partial thromboplastin time (PTT) =< 1.2 X ULN (evaluated within 28 days of randomization)
Partial thromboplastin time less than 2.5 times below or above the upper or lower limit range; for those patients receiving Coumadin or another anticoagulant the upper limit for partial thromboplastin time must not exceed 6 times the upper limit of the normal range
Pre-treatment laboratory tests for patients receiving fluorine F 18 fluorothymidine ([18F]FLT) must be performed within 21 days prior to baseline imaging; these laboratory tests must be less than 4.0 times below or above the upper or lower limit range for the respective laboratory test for entry into the study (unless not clinically relevant); 2.5 x for prothrombin time and partial thromboplastin time; for those patients receiving Coumadin or another anticoagulant the upper limit for prothrombin time or partial thromboplastin time must not exceed 6 times the upper limit of the normal range; the initial 4.0 x value will be critical for liver function test results which can be extremely variable, and a 4.0 x above the upper normal range is still acceptable for inclusion in this study; urinalysis abnormalities will not preclude the patient from being enrolled and studied; the baseline and subsequent laboratory testing will include liver enzymes (serum glutamic oxaloacetic transaminase [SGOT], serum glutamate pyruvate transaminase [SGPT], anaplastic lymphoma kinase [ALK]), bilirubin (total), serum electrolytes, complete blood count (CBC) with platelets prothrombin time, partial thromboplastin time, blood urea nitrogen (BUN), and creatinine
For the follow-up scanning sessions after therapy has been instituted and within 7 days prior to the second [18F]FLT study the laboratory assessments will be required due to the use of [18F]FLT; these studies should also be less than 4.0 times below or above the upper or lower limit range for the respective laboratory study (unless not clinically relevant); 2.5 x for prothrombin time and partial thromboplastin time; however at the discretion of the study principal investigator (PI) the second imaging sessions can occur if laboratory values are not within the 4 X upper limit of normal (unless not clinically relevant); for those patients receiving Coumadin or another anticoagulant the upper limit for prothrombin time or partial thromboplastin time must not exceed 6 times the upper limit of the normal range; for the assessments at subsequent imaging time points the laboratory tests as described for baseline assessment will again be obtained
internal normalized ratio and partial thromboplastin time <1.5x upper limit of normal
Activated partial thromboplastin time (aPTT) =< 1.5 x ULN
Activated partial thromboplastin time (aPTT) =< 1.2 x ULN
Activated partial thromboplastin time (aPTT) =< 1.2 X ULN
Activated partial thromboplastin time (APTT) or partial thromboplastin time (PTT) =< 1.5 x institutional upper limit of normal
Activated partial thromboplastin time (aPTT) =< 1.5 x institutional ULN (for participants on anticoagulation therapy, =< 1.5 x their baseline value)
Activated partial thromboplastin time (aPTT) =< 1.5 x institutional ULN (for participants on anticoagulation therapy, =< 1.5 x their baseline value)
Activated partial thromboplastin time (aPTT) within normal limits
PTT or activated partial thromboplastin time (aPTT) ?5 seconds above institutional ULN
Activated partial thromboplastin time (aPTT) ?1.5 × ULN (Grade ?1).
Activated partial thromboplastin time (APTT) or partial thromboplastin time (PTT) =< 1.5 x institutional upper limit of normal
Activated partial thromboplastin time/ partial thromboplastin time (aPTT/PTT) ? 1.5 x ULN
Activated partial thromboplastin time (aPTT) > 35.9 seconds
Partial thromboplastin time (PTT)/activated (a)PTT =< 1.5 X institutional ULN normal except if, in the opinion of the investigator, the aPTT is elevated because of a positive lupus anticoagulant (unless dysfunction is secondary to lymphoma involvement)
Activated partial thromboplastin time (aPTT) =< 1.5 X ULN
Partial thromboplastin time (PTT) or activated PTT (aPTT) =< 1.5 x ULN
Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin) (obtained within 28 days prior to first study treatment)
Activated partial thromboplastin time (aPTT) within 1.25 x ULN institutional limits, except where a lupus anti-coagulant has been confirmed
Activated partial thromboplastin time (aPTT) < 1.5 x ULN
Partial thromboplastin time (PTT) (PTT/activated partial thromboplastin time [aPTT]) < 1.5 x ULN)
Within 3 months of registration: Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)
Activated partial thromboplastin time (aPTT) =< 1.5 x ULN for the laboratory
Activated partial thromboplastin time (aPTT) =< 1.2 x IULN
Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless the patient is receiving anticoagulant therapy
Activated partial thromboplastin time (aPTT) =< 1.2 x ULN
Activated partial thromboplastin time/ partial thromboplastin time (aPTT/PTT) ?1.5 x ULN
Activated partial thromboplastin time (aPTT) =< 1.5 x ULN or within therapeutic range if receiving anticoagulant therapy OR
Activated partial thromboplastin time (APTT)/PTT =< 1.5 x institutional ULN
Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =< 1.5 x ULN
Activated partial thromboplastin time (aPTT) =< 1.5 x ULN for the laboratory
ARM A: obtained =< 14 days prior to registration: \r\n* Activated partial thromboplastin time (aPTT) =< 1.5 x ULN
Obtained within 30 days prior to registration: Activated partial thromboplastin time (aPTT) =< 2 x ULN (Note: use of vitamin K antagonist is not allowed)
Activated partial thromboplastin time (APTT) or partial thromboplastin time (PTT) =< 1.5 x institutional upper limit of normal
Activated partial thromboplastin time (aPTT) =< 1.2 x ULN
Activated partial thromboplastin time (APTT) < 1.2 times upper limit of normal (ULN); (Note: use of warfarin is prohibited; low molecular weight heparin is allowed, so long as these criteria are met)
Activated Partial Thromboplastin Time (APTT) patients beeing treated with anticoagulants are excluded if teh coagulation parameters are outside the therapeutic intervals as described in the SmPC/USPI for the administered treatment
Activated Partial Thromboplastin Time (aPTT) ?1.5 X ULN
Activated partial thromboplastin time (aPTT) =< 1.2 x ULN (tested within 14 days prior to registration)
Activated partial thromboplastin time (aPTT) =< 1.2 x ULN
Activated partial thromboplastin time (aPTT) =< 1.2 x IULN
Partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) =< upper limit of normal (ULN) per institutional laboratory range
Activated partial thromboplastin time (aPTT) > 1.5 x ULN (patients on heparin treatment must have an aPTT between 1.5 - 2.5 x ULN), or
Activated partial thromboplastin time (aPTT) =< 1.5 x institutional upper limits of normal
Activated partial thromboplastin time (aPTT) =< 1.2 X ULN; subjects receiving anticoagulant therapy are eligible if their aPTT is stable and within the recommended range for the desired level of anticoagulation
Activated partial thromboplastin time (aPTT) =< 1.2 X ULN
Activated partial thromboplastin time (aPTT) =< 1.2 X ULN
Activated partial thromboplastin time (aPTT) =< 1.2 X ULN
Activated partial thromboplastin time (aPTT) =< 1.2 x ULN
Prothrombin time and activated partial thromboplastin time (aPTT) < 1.5 times the upper limit of normal (ULN)
Activated partial thromboplastin time (aPTT) ? 1.5 x the upper limit of the normal range (ULN) per institutional laboratory normal range
Activated partial thromboplastin time (aPTT) ? 1.5 x the upper limit of the normal range (ULN) per institutional laboratory normal range
Activated partial thromboplastin time (APTT) =< 1.5 x upper limit of normal unless patient is receiving anticoagulants; if patient is on anticoagulation therapy, levels should be within therapeutic range
Activated partial thromboplastin time (PTT) < 1.5 x ULN
Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =< 1.5 x institutional upper limit of normal
aPTT ? 1.5 x ULN
Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =< 1.5 x institutional upper limit of normal
Activated partial thromboplastin time =< 1.5 times ULN
Activated partial thromboplastin time =< 1.5 times ULN
Activated partial thromboplastin time (aPTT) ? 1.3 × ULN
Abnormal coagulation (partial thromboplastin [PT] or activated partial thromboplastin time [aPTT] > 30% above normal limits)
Within 30 days of surgery: Activated partial thromboplastin time (aPTT) =< 40
Activated partial thromboplastin time (APTT) or partial thromboplastin time (PTT) =< 1.5 x institutional upper limit of normal
Partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) =< 1.5 times the upper limit of normal
Activated partial thromboplastin time (aPTT) =< 40 (within 30 days of surgery)
Activated partial thromboplastin time (aPTT) within normal institutional limits
Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =< 1.5 x institutional upper limit of normal
Obtained within 28 days prior to registration: Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)
Activated partial thromboplastin time (aPTT) or plasma thromboplastin (PT) outside the institution's standard of care.
Within 10 days of treatment initiation: Prothrombin time (PT) and partial thromboplastin time (aPTT) =< 1.5 X institutional upper limit of normal (IULN)
Prothrombin time (PT) and partial thromboplastin time (PTT) =< 1.5 x ULN
Prothrombin time (PT)/partial thromboplastin time (PTT) =< 2 times normal; timeline: within 3 weeks prior to enrollment or
If requires pheresis to collect blood, prothrombin time (PT) < 1.5 upper limit normal
Prothrombin time (PT)/partial thromboplastin time (PTT) =< 1.5 X upper limit of normal (ULN) unless receiving clinically indicated anticoagulant therapy
PART I: Prothrombin time (PT)/partial thromboplastin time (PTT) =< 1.5 x the upper limits of normal
Normal prothrombin time (PT)
Normal prothrombin time (less than or equal to 15.2 seconds)
Prothrombin time (PT)/partial thromboplastin time (PTT) > 1.5 upper limit of normal (ULN)
Prothrombin time (PT)/partial thromboplastin time (PTT) less than 1.5 times normal
Prothrombin time (PT)/partial thromboplastin time (PTT) =< 1.5 x ULN
Prothrombin time (PT), partial thromboplastin time (PTT) =< 1.5 times upper limit of normal
Prothrombin time (PT) ?1.5 × ULN (Grade ?1).
Prothrombin time (PT) > 16.5 seconds or
Prothrombin time (PT) within normal limits (WNL)+/- 15 % unless on active anticoagulation obtained ? 14 days prior to randomization
Prothrombin time (PT)/partial thromboplastin time (PTT) ? 1.5 times the ULN
Prothrombin time (PT) no more than 2 seconds above the upper limits of normal (ULN)
Within 7 days (+ 3 day window) of enrollment: Prothrombin time (PT) and partial thromboplastin time (PTT) =< 1.5 x the institutional upper limit of normal (ULN), (this will not apply to subjects with confirmed Factor XII deficiency)
Prothrombin time (PT) and partial thromboplastin time (PTT) must be =< 2 x the upper limit of the institution's normal range, at the time of enrollment
Obtained =< 28 days prior to registration: Prothrombin time (PT) =< 1.5 x upper limit of normal (ULN) unless patient is receiving anticoagulant therapy and PT or partial prothrombin time (PTT) is within therapeutic range of intended use of coagulants
Prothrombin time (PT) < 1.5
Hepatic: Total bilirubin 1.5 x ULN; transaminases ? 2.5 x ULN (may be up to 5 x ULN if clearly due to liver metastases); prothrombin time (PT) and partial thromboplastin time (PTT) < 2 x (ULN).
A Prothrombin Time (PT) or Partial Thromboplastin Time (PTT) within normal range
Prothrombin time (PT) =< 1.5 x ULN
Prothrombin time (PT)/partial thromboplastin time (PTT) =< 1.5 x ULN
Obtained within 14 days prior to registration; prothrombin time and partial thromboplastin time (PT / PTT) ? 50% increase from institutional ULN
Prothrombin time (PT) and partial thromboplastin time (PTT) > 50% of deviation of institutional ULN
Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 x upper limit of normal (ULN)
Prothrombin time (PT) < 1.5
Prothrombin time (PT) and partial thromboplastin time (PTT) =< 1.5 x ULN after correction of nutritional deficiencies that may contribute to prolonged PT/PTT
No baseline prothrombin time (PT)/partial thromboplastin time (PTT) abnormalities, coagulopathies, or who are on any blood thinners
Prothrombin time =< 1.5 x upper limit of normal (ULN) obtained within 14 days of first treatment
Prothrombin time (PT) =< 1.5 x ULN
Prothrombin time (PT) =< 1.5 x institutional upper limit of normal (ULN)
Prothrombin time (PT) < 14 sec; partial thromboplastin time (PTT) < 35 sec
Prothrombin time (PT), partial thromboplastin time (PTT) =< 1.5 x ULN
Prothrombin time (PT) and partial thromboplastin time (PTT) < 50% of deviation from institutional upper limit of normal (IULN)
Normal prothrombin time (PT) for age
Prothrombin time (PT) no greater than 6 seconds longer than control.
Prothrombin time (PT) < 1.3 x upper limit of normal (ULN)
Prothrombin time (PT) with normal limits (WNL); if patient is on warfarin for prophylactic clot presentation for indwelling catheter, PT/partial thromboplastin time (PTT) may be +/- 15 %
Evidence of bleeding diathesis or coagulopathy as documented by an elevated prothrombin time (PT), partial thromboplastin time (PTT) or bleeding time
Prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (secpatient may be eligible for trial if abnormality is deemed clinically insignificant and cleared for protocol therapy by Hematology Consult service)
Prothrombin time (PT)/partial thromboplastin time (PTT) =< 1.4 times upper limit of normal range
Prothrombin time (PT) and partial thromboplastin time (PTT) =< 2 x normal outside the setting of stable chronic anticoagulation therapy
Prothrombin time less than 1.5 × ULN for the institution
Prothrombin time (PT)/partial thromboplastin time (PTT) =< 1.5 x upper limit of normal (ULN) unless receiving clinically indicated anticoagulant therapy
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Prothrombin time (PT) and partial thromboplastin time (PTT) < 1.4 x ULN
HPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Prothrombin time (PT) and partial thromboplastin time (PTT) < 1.4 x ULN
Prothrombin time (PT) and/or partial thromboplastin time (PTT) =< 1.5 X ULN.
Prothrombin time/partial thromboplastin time (PT/PTT) ? 1.5 x upper limit of normal (ULN) (unless receiving anticoagulation)
Prothrombin time (PT) =< 1.5 x ULN
Prothrombin time (PT) and partial thromboplastin time (PTT) ? 1.5 x of institutional upper limit of normal (ULN) (Note: If coagulopathy is related to disease, this criteria do not apply) within 14 days prior to registration
Prothrombin time (PT)/partial thromboplastin time (PTT) < 1.5 x normal institutional standard
Prothrombin Time (PT) and activated partial thromboplastin time (PTT) ? 1.6x unless therapeutically warranted
Prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (11.6 - 15.2 / 25.3 - 37.3 sec)
Prothrombin time (PT) > 12 seconds or partial thromboplastin time (PTT) > 31 seconds
Prothrombin time (PT) within 2 seconds of the upper limit of normal (ULN)
Prothrombin time (PT) and partial thromboplastin time (PTT) =< 2 x ULN
Prothrombin time (PT) and partial thromboplastin time (PTT) =< 1.5 x upper limit of normal (ULN)
Prothrombin time (PT) =< 1.2 x ULN
Prothrombin time (PT) and partial thromboplastin time (PTT) within 1.5 times the institutional upper limit of normal
Normal coagulation [prothrombin time and partial thromboplastin time within normal limits (±15%)].
Prothrombin time (PT) or partial thromboplastin time (PTT) test >= 1.3 x laboratory upper limit of normal (ULN) within 7 days before the first dose of study treatment
Prothrombin time (PT) and partial thromboplastin time (PTT) ? 1.5 X ULN after correction of nutritional deficiencies that may have contributed to prolonged PT/PTT.
AMKL PATIENTS: Prothrombin time (PT) and partial thromboplastin time (PTT) =< 1.5 x ULN
Coagulation: Prothrombin time (PT) <1.5 × ULN and partial thromboplastin time (PTT) <1.5 × ULN
Acceptable coagulation studies as demonstrated by prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits (+/-15%).
Prothrombin time (PT) and partial thromboplastin time (PTT) < 1.4x the ULN
Prothrombin time (PT) and partial thromboplastin time (PTT) > 50% of deviation of institutional upper limit of normal (ULN)
Prothrombin time (PT) =< 1.5 times the upper limit of normal
Prothrombin time (PT) within normal limits (UIHC)
Adequate coagulation defined as:\r\n* Prothrombin time (PT) =< 1.2 x upper limit of normal
Prothrombin time (PT) < 1.2 x ULN
Patients must NOT have a prolonged prothrombin time (PT) or partial thromboplastin time (PTT) (greater than 1.2 times the institutional upper limit of normal)
Prothrombin time (PT) and partial thromboplastin time (PTT) > 50% of deviation of institutional ULN
Other: Prothrombin time (PT) and partial thromboplastin time (PTT) < ULN.
Prothrombin time (PT) and partial thromboplastin time (PTT) =< 2 x ULN
Prothrombin time (PT)/partial thromboplastin time (PTT) =< 1.5 x upper limit of normal (ULN)
Prothrombin time (PT)/partial thromboplastin time (PTT) =< 1.5 x upper limit of normal (ULN)
Normal prothrombin time (PT)/partial thromboplastin time (PTT)
prothrombin time (PT) and activated partial thromboplastin time (PTT) ? 1.6 x control unless therapeutically warranted
Prothrombin time (PT) and partial thromboplastin time (PTT) must not be more than 1.5 x upper limit of normal (ULN) within 72 hours prior to enrollment; PT and PTT should be drawn by venipuncture, rather than from a central venous catheter when feasible
Prothrombin time (PT) and partial thromboplastin time (PTT) < 2 x normal outside the setting of stable chronic anticoagulation therapy
Prothrombin time (PT)/partial thromboplastin time (PTT) =< 1.5 x institutional upper limits of normal
Prothrombin time (PT) and partial thromboplastin time =< 1.5 upper limit of normal (ULN) unless using warfarin for therapeutic anti-coagulation
Subjects must have normal coagulation parameters as measured by prothrombin time (PT)/partial thromboplastin time (PTT)
Prothrombin time (PT)/INR and partial thromboplastin time (PTT) =< grade 1 within two weeks before initial biopsy of visceral organs
Prothrombin time (PT) =< 2 x normal outside the setting of stable chronic anticoagulation therapy
Prothrombin time (PT) and partial thromboplastin time (PTT) =< 1.2 X upper limit normal (ULN)
Prothrombin time (PT) and partial thromboplastin time (PTT) < 2 x normal outside the setting of stable chronic anticoagulation therapy
Prothrombin time (PT) and partial thromboplastin time (PTT) =< 120% of control, unless patient has the presence of a lupus anticoagulant
Prothrombin time (PT), partial thromboplastin time (PTT) less than or equal to 1 to 1.5 x upper limit of normal, CTCAE v 4.0 grade 1 except for patients on therapeutic anticoagulation
Prothrombin time (PT)/partial thromboplastin time (PTT) =< 1.5 X ULN
Prothrombin time < 1.5 x ULN
Normal prothrombin time
Prothrombin time (PT) ? 1.5 x ULN
TREATMENT: Prothrombin time (PT) within 2 seconds of the upper limit of normal (ULN)
Coagulation status: prothrombin time (PT) ? 1.5 ULN or INR within normal limits; and partial thromboplastin time (PTT) ? 1.2 × ULN
No evidence of coagulopathy as indicated by prothrombin time (PT) =< 1.5 X upper limit of normal
Patients with known bleeding diathesis or prothrombin time (PT) or aPTT >1.5 x ULN or fibrinogen <0.5 x LLN
PART I: Absolute neutrophil count (ANC), hemoglobin, platelet, total bilirubin, creatinine, transaminase (aspartate aminotransferase [AST]/alanine aminotransferase [ALT]), prothrombin time (PT), partial thromboplastin time (PTT), urine uric acid, urine pH, urine oxalate must be within standard normal ranges
Prothrombin time (PT)/partial thromboplastin time (PTT) < 1.5 x upper limit of normal (ULN)
Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 x institutional upper limit of normal (IULN)
Prothrombin time (PT) =< 4 seconds above upper limit of normal (ULN) and partial thromboplastin time (PTT) =< 10 seconds above ULN
Prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (WNL) of the institution
Prothrombin time (PT) or partial thromboplastin time (PTT) > 1.5 x the upper limit of normal, except if the patient is on therapeutic anticoagulation, in which case they should demonstrate stability of PT/PTT for at least two weeks
Prothrombin time (PT) < 1.5 ULN
Prothrombin time (PT) =< 1.5 times upper limit of laboratory normal (ULN)
Prothrombin time (PT) no more than 2 seconds above the upper limit of normal (ULN)
Prothrombin time (PT) =< 1.5 times upper limit of laboratory normal (ULN)
Prothrombin time > 1.5 x control
Have a bleeding disorder as determined by prothrombin time (PT) > 14.5 seconds, partial thromboplastin time (PTT) > 34 seconds, and platelet count < 140,000 platelets per microliter of circulating blood1
Prothrombin time (PT) and partial thromboplastin time (PTT) > 1.5 x ULN
Prothrombin time (PT) and partial thromboplastin (PTT) =< 1.5 x IULN
Prothrombin time greater than 50% of control
Prothrombin time (PT) and partial thromboplastin time (PTT) =< 1.5 x institutional upper limit of normal
Prothrombin time (PT)/partial thromboplastin time (PTT) within normal institutional limits
Presence of coagulopathy (prothrombin time [PT] or partial thromboplastin time [PTT] > 1.2 x upper limit of normal)
Thrombin time (TT), prothrombin time (PT), or partial thromboplastin time (PTT) > 2 x upper limit of normal
Patients not taking warfarin must have prothrombin time (PT)/partial thromboplastin time (PTT) levels =< 1.5 times the upper limit of normal provided by the reference laboratory performing the test
Prothrombin time (PT)/partial thromboplastin time (PTT) within normal institutional limits
PT/PTT/INR (prothrombin time/partial thromboplastin time) without clinically significant abnormalities after review by the study physicians
Contraindication to biopsy:\r\n* Bleeding disorders\r\n* Prothrombin time (PT)/partial thromboplastin time (PTT) >= 1.5 times the upper limit of normal\r\n* Artificial heart valve
Patients with coagulopathies who are at increased risk for bleeding or on active anti-coagulation therapy (platelets less than 100,000 per mm^3 or prothrombin time [PT]/partial thromboplastin time [PTT] greater than 1.5 times the upper normal limit [UNL]); patients are eligible if the underlying cause is correctable
Prothrombin time (PT)/partial thromboplastin time (PTT) =< the institution ULN
Prothrombin time > 1.5 x control
Coagulopathy (prothrombin time [PT] or partial thromboplastin time [PTT] > 1.5 x upper limit of normal)
Prothrombin time (PT), partial thromboplastin time (PTT) =< 1.5 times upper limit of normal
PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN
Coagulation: PT > 4 seconds more than ULN or INR > 1.7
PTT =< 1.3 x ULN
PTT > 1.3 x ULN
INR > 1.3
Abnormal coagulation profile (PT or INR, PTT) > 1.3x ULN
PT/INR ? ULN within 28 days of randomization. Patients receiving therapeutic anti-coagulants are not eligible.
INR < 1.5 × ULN
PT and PTT <1.5 x ULN
PT and PTT w/in ?1.5× ULN
INR ?1.5× ULN
PHASE IB: PT (or INR) and PTT =< 1.5 x ULN
PART II: PT/PTT =< 1.5 x the upper limits of normal
PTT & INR within institutional limits.
PT-INR > 2x upper limit of normal reference range (ULN) in the absence of anticoagulation within 7 days prior to Day 1
INR ? 1.5
INR < 1.5 × ULN
Patients on a stable dose of anti-coagulation therapy will be allowed to participate if they have no signs of bleeding or clotting and the INR/PT and PTT/aPTT results are compatible with an acceptable risk-benefit ratio as per the investigator’s discretion
INR ? 1.5 x ULN;
Normal PT/INR and PTT;
FULL STUDY INCLUSION CRITERIA: Partial thromboplastin time (PTT) or activated PTT (aPTT) =< 1.5 x ULN (CTCAE grade =< 1)\r\n* Note: patients on stable dose of anti-coagulation therapy will be allowed to participate if they have no sign of bleeding or clotting and INR / PT and PTT / aPTT test results are compatible with the acceptable benefit-risk ratio at the investigator’s discretion
INR ?1.5
INR > 2
Acceptable coagulation status: INR ?2.0 x ULN and PTT ?2.0 x ULN.
INR >= 2
PT and PTT <1.5 ULN
INR and APTT ? 1.5 x ULN.
Patients must have INR and PTT values ? 1.5X ULN for the reference laboratory.
PTT WNL; if patient on warfarin for prophylactic clot presentation for indwelling catheter, PT/PTT may be +/- 15 %
Abnormal level of platelets (< 100000), PT (>14) or PTT (>36), and INR > 1.3.
PT and PTT ? 1.5 X ULN
Patients with PT/PTT above the upper limit of normal
PTT =< 1.5 x ULN unless on anticoagulation therapy, in which case PT or PTT should be in the therapeutic range
INR > 2.5
INR =< 1.5
For patients on Coumadin, INR/prothrombin time (PT)/PTT must be > 1.5 ULN
PT ?1.5 ULN
PTT ?1.5 ULN
INR < 1.5 or PTT value < 1.5 x upper limit of normal (ULN) at study entry
Bleeding disorder (INR > ULN and PTT > ULN)
PT <1.5 ULN
PTT <1.5 ULN
MF PATIENTS: PT and PTT =< 1.5 x ULN
PT, PTT (in seconds) not to be prolonged beyond >20% of the upper limits of normal.
INR and PTT within 1.5 X institutional ULN
INR < 2.0
PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN
PT/INR, PTT, and fibrinogen within institutional acceptable limits
For patients not taking warfarin: INR ?1.5 or PT ?1.5 × ULN; and either PTT or aPTT ?1.5 × ULN. Patients taking warfarin should be on a stable dose that results in a stable INR <3.5.
INR < 1.5 × ULN
pT3, G any, N1; or, pT4, G any, N1; or, pT any, G any, N1 or M1)
INR and aPTT < 1.5 X ULN unless on medication known to alter INR and aPTT.
Screen labs of Hemoglobin, platelets, absolute neutrophil count (ANC), bilirubin, AST, ALT, serum creatinine, serum albumin, PT/INR, and PTT within specified values/criteria per protocol prior to dosing.
The patient has a PT (or INR) and PTT up to 1.25×ULN
INR < 1.5 × ULN
INR and aPTT within 1.5 ULN
PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN (When treated with warfarin or other vitamin K antagonists, then INR ?3.0).
INR > 1.5
Normal PT or INR and aPTT
PT/INR <1.5 x ULN and PTT/ aPTT <1.5 x ULN
PT/aPIT ? 1.5 x ULN
INR ? 1,5
PT/INR and aPTT ? 1.5 ULN.
Patients with pT3 or pT4 disease
PT/PTT > the institution ULN
